Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
CSTL Castle Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: CSTL
Price (delayed)
$17.21
Market cap
$496.89M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.15
Enterprise value
$433.05M
Castle Biosciences is a commercial-stage dermatologic cancer company focused on providing physicians and their patients with personalized, clinically actionable genomic information to make more accurate treatment decisions. The Company currently
Highlights
The gross profit has grown by 41% YoY and by 4.6% from the previous quarter
CSTL's revenue is up by 38% YoY and by 4.5% from the previous quarter
The net income has dropped by 128% since the previous quarter but it has surged by 84% year-on-year
CSTL's EPS has dropped by 123% since the previous quarter but it has surged by 87% year-on-year
The debt has increased by 3.2% YoY
Key stats
What are the main financial stats of CSTL
Market
Valuations
Earnings
Shares outstanding
28.87M
Market cap
$496.89M
Enterprise value
$433.05M
Price to earnings (P/E)
N/A
Price to book (P/B)
1.11
Price to sales (P/S)
1.42
EV/EBIT
N/A
EV/EBITDA
10.62
EV/Sales
1.25
Revenue
$347.08M
Gross profit
$284.39M
Operating income
-$13.79M
Net income
-$5.07M
EBIT
-$1.64M
EBITDA
$40.78M
Free cash flow
$41.77M
Per share
Balance sheet
Liquidity
EPS
-$0.15
EPS diluted
-$0.19
Free cash flow per share
$1.46
Book value per share
$15.44
Revenue per share
$12.13
TBVPS
$14.81
Total assets
$501.72M
Total liabilities
$61.41M
Debt
$25.84M
Equity
$440.31M
Working capital
$312.11M
Debt to equity
0.06
Current ratio
9.37
Quick ratio
8.92
Net debt/EBITDA
-1.57
Margins
Efficiency
Dividend
EBITDA margin
11.8%
Gross margin
81.9%
Net margin
-1.5%
Operating margin
-4%
Return on assets
-1%
Return on equity
-1.2%
Return on invested capital
-0.6%
Return on capital employed
-0.4%
Return on sales
-0.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CSTL stock price
How has the Castle Biosciences stock price performed over time
Intraday
0.94%
1 week
-10.88%
1 month
-7.47%
1 year
-26.89%
YTD
-35.42%
QTD
-14.04%
Financial performance
How have Castle Biosciences's revenue and profit performed over time
Revenue
$347.08M
Gross profit
$284.39M
Operating income
-$13.79M
Net income
-$5.07M
Gross margin
81.9%
Net margin
-1.5%
The net income has dropped by 128% since the previous quarter but it has surged by 84% year-on-year
The net margin has shrunk by 127% QoQ but it has soared by 88% YoY
The operating margin has surged by 76% year-on-year
The operating income has soared by 67% YoY
Price vs fundamentals
How does CSTL's price correlate with its fundamentals
Growth
What is Castle Biosciences's growth rate over time
Valuation
What is Castle Biosciences stock price valuation
P/E
N/A
P/B
1.11
P/S
1.42
EV/EBIT
N/A
EV/EBITDA
10.62
EV/Sales
1.25
CSTL's EPS has dropped by 123% since the previous quarter but it has surged by 87% year-on-year
CSTL's price to book (P/B) is 54% lower than its 5-year quarterly average of 2.4 and 26% lower than its last 4 quarters average of 1.5
The equity is up by 9% year-on-year but it has declined by 3.4% since the previous quarter
The P/S is 84% below the 5-year quarterly average of 8.8 and 32% below the last 4 quarters average of 2.1
CSTL's revenue is up by 38% YoY and by 4.5% from the previous quarter
Efficiency
How efficient is Castle Biosciences business performance
The ROE has shrunk by 129% QoQ but it has soared by 85% YoY
Castle Biosciences's return on assets has shrunk by 127% QoQ but it has surged by 86% YoY
Castle Biosciences's return on invested capital has shrunk by 108% QoQ but it has surged by 96% YoY
CSTL's return on sales has dropped by 107% since the previous quarter but it has surged by 96% year-on-year
Dividends
What is CSTL's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CSTL.
Financial health
How did Castle Biosciences financials performed over time
CSTL's current ratio is up by 29% since the previous quarter
Castle Biosciences's quick ratio has increased by 28% QoQ
The debt is 94% lower than the equity
The equity is up by 9% year-on-year but it has declined by 3.4% since the previous quarter
The debt has increased by 3.2% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.